Escitalopram Market

2021-2030 Analysis and Review Escitalopram Market

Escitalopram Market

Escitalopram Market By Disease (Major Depression Disorder, Generalized Anxiety Disorder, Obsessive Compulsive Disorder and Post-Traumatic Stress Disorder), By End User (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

20-01-2020 REP-HC-5011 116 pages Format

The Escitalopram market was valued at USD3,249.7 Mn by 2019. Rising prevalence of major depressive disorder throughout the globe and the availability of low-cost generic versions of Escitalopram together drive the market growth. Furthermore effective implementation of treatment guidelines pertaining to mental health will bolster its market growth in the near future. The major hurdle faced by this market is cut-throat completion imposed by other antidepressants such as Citalopram and Fluoxetine.

 Escitalopram Market

Escitalopram has been included in the World Health Organization (WHO), a list of essential medicines for the treatment of major depressive disorder in patients above 18 years. Since the drug has become generic there has been a significant reduction in its cost and hence it is frequently prescribed by psychiatrists throughout the globe. The medicine is available in tablet, capsule, and liquid dosage form, its composition strength varies according to the disorder it is prescribed to treat. Escitalopram is had relatively improved side effects profile in comparison to other antidepressants and has been confirmed by a clinical trial investigation that it causes minimal damage to the hepatic cytochrome enzymes and is well tolerated in elderly patients.

The major segments related to the Escitalopram market are:

By Disease (2017–2027; US$ Mn)

Major Depression Disorder

Generalized Anxiety Disorder

Obsessive Compulsive Disorder

Post-Traumatic Stress Disorder

By End User (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy


Geography Segment(2017–2027; US$ Mn)

North America

United States


United Kingdom
Rest of Europe

Asia Pacific

Rest of Asia Pacific

Latin America (LATAM)

Rest of Latin America

Middle East and Africa (MEA)

Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global Escitalopram market
  • The overall segmentation of the Escitalopram market, by disease, end-user, and geography is minutely studied. Major depression disorder and hospital pharmacy are dominating the disease and end-user segments respectively
  • Significant rise in post-traumatic stress disorder throughout the globe and availability of generic versions of Escitalopram at relatively low cost together drive the market growth
  • Effective implementation of treatment guidelines pertaining to mental health further propels Escitalopram 

Report gist?

  • The study of the global Escitalopram market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers qualitative and quantitative analysis of the overall market segmented on the basis of disease and end-user and categorization of the same at geography level
  • This research report presents the analysis of each segment from 2017 to 2027 considering 2019 as the base year for the research. CAGR for each respective segments are calculated for the forecast period from 2020 to 2027
  • The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical companies engaged in manufacturing and marketing of Escitalopramwhich is gaining huge demand due to significant rise in mood disorders and availability of Escitalopram in its generic version at low cost
  • The report will benefit psychiatrist prescribing medicines to treat mental illness
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to Escitalopram market
  • Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies

Segment Analysis

Major depression disorder is leading the disease segment for the Escitalopram market. According to the Center for Disease Control (CDC) the occurrence of major depressive disorder is related to frequent bouts of mood swings, insomnia, and money-related stress. It is a disease highly prevalent among the developing nations owing to deteriorated socioeconomic conditions that affect the mental health of the individual. Post-traumatic stress disease is anticipated to register remarkable growth in the near future on account of lack of social life, sedentary lifestyle, self-destructive behavior, and overwhelming guilt which are seldom encountered in the younger generation worldwide.

Hospital pharmacy is currently dominating the end-user segment for the Escitalopram market. The inherent features associated with hospital pharmacy which are responsible for its paramount market growth are, individual medication order system, unit dose system, an automatic medication dispensing which are beneficial which dispensing medications intended to treat mental and mood disorders. Retail pharmacies are gaining prominence on account of its ability to maintain bulk stock of generic Escitalopram medicine and the potential to cater to the medical requirement of patients in remote locations.

North America is the global leader in the geography segment for the Escitalopram market. As per the latest statistics provided by the World Health Organization (WHO), in the United States annually more than 25.3 million prescriptions of Escitalopram are sold. According to the research citings provided by the National Institute for Health (NIH), approximately 8 million U.S. citizens are diagnosed with post-traumatic stress disorder. Effective implementation of treatment guidelines associated with mental health will further bolster the Escitalopram market growth in the region. In Europe the market growth is primarily determined by the rising prevalence of generalized anxiety disorder. According to the European Commission Report, approximately 19.5% of the disease burden in the European region is associated with neuropsychiatric disorders. The affordable reimbursement scenario further facilitates the Escitalopram market growth in the region. Asia Pacific is keen to project steady market growth owing to the rising prevalence of obsessive-compulsive disorder and the presence of a huge generic market.

Select License Type


Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1569

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.